Clinical Scorecard: Effectiveness of Immune Checkpoint Inhibitors in Reducing Venous Tumor Thrombus in Renal Cell Carcinoma (UroCCR 128)
At a Glance
Category
Detail
Condition
Renal Cell Carcinoma with Venous Tumor Thrombus (VTT)
Key Mechanisms
Immune checkpoint inhibitors (ICIs) modulate immune response to target tumor cells; combined with VEGFR-targeted therapies or other ICIs to improve survival and response rates
Target Population
Patients with locally advanced or metastatic renal cell carcinoma presenting with venous tumor thrombus
Care Setting
Multicentric European oncology centers; systemic therapy with ICIs as first-line or beyond
Key Highlights
VTT occurs in 4–10% of localized RCC and complicates surgical management with higher morbidity and poor prognosis
ICI-based therapies have shown improved overall survival and response rates compared to sunitinib in metastatic RCC
Retrospective study of 44 patients showed use of ICIs (alone or combined) in RCC with VTT, with radiological assessment per RECIST v1.1 and Novick’s classification
Guideline-Based Recommendations
Diagnosis
Histological confirmation of RCC with VTT at diagnosis
Radiological assessment using CT or MRI to evaluate tumor and thrombus extent
Classification of VTT extent using Novick’s classification (levels I-IV)
Management
First-line treatment with ICI-based regimens (ICI-ICI, ICI-TKI, or ICI monotherapy) for metastatic RCC with VTT
Consider radical nephrectomy and tumor thrombectomy for localized disease or delayed surgery after systemic therapy
Dose reductions permitted for toxicity based on standard recommendations
Monitoring & Follow-up
Radiological tumor assessment using RECIST v1.1 criteria to evaluate objective response rate
Regular imaging follow-up to assess VTT size and extension
Clinical and laboratory monitoring per institutional protocols
Risks
High morbidity associated with surgery for VTT, especially with vena cava involvement
Potential toxicity from ICI-based therapies requiring dose adjustments
Poor prognosis despite treatment, with 5-year survival rates of 40–60% in VTT patients
Patient & Prescribing Data
44 patients with locally advanced or metastatic RCC with VTT; median age 69; majority clear cell carcinoma; IMDC intermediate or poor risk
82% treated first-line with ICI-based therapy; regimens included ICI-ICI (52%), ICI monotherapy (30%), and ICI-TKI (18%); median VTT diameter 22 mm; some patients underwent delayed nephrectomy and thrombectomy after systemic therapy
Clinical Best Practices
Use multidisciplinary approach including oncologists, radiologists, and surgeons for management of RCC with VTT
Employ standardized imaging and classification systems (RECIST v1.1 and Novick’s) for consistent assessment
Consider neoadjuvant ICI-based therapy to potentially reduce VTT extension and facilitate surgery
Monitor patients closely for treatment response and toxicity, adjusting doses as needed
Recognize the high surgical morbidity and tailor treatment plans accordingly
by Fabien Moinard-Butot, Jonathan Thouvenin, Pierre Bigot, Nieves Martinez-Chanza, Victor Gaillard, Roberto Luigi Cazzato, Romain Boissier, Gaëlle Margue, Philippe Boudier, Denis Maillet, Marine Gross-Goupil, Jean-Christophe Bernhard, Philippe Barthélémy
